Shopping Cart 0
Cart Subtotal
AED 0

Pharmaceuticals North America (NAFTA) Industry Guide 2014-2023

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 2918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 5835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 8753

Details

Pharmaceuticals North America (NAFTA) Industry Guide 2014-2023

Summary

The NAFTA Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the NAFTA pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

Key Highlights

- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The pharmaceuticals industry within the NAFTA countries had a total market value of USD 437.0 billion in 2018.The Mexico was the fastest growing country, with a CAGR of 4.6% over the 2014-18 period.

- Within the pharmaceuticals industry, the US is the leading country among the NAFTA bloc, with market revenues of USD 392.8 billion in 2018. This was followed by Canada and Mexico, with a value of USD 23.5 and USD 20.7 billion, respectively.

- The US is expected to lead the pharmaceuticals industry in the NAFTA bloc, with a value of USD 484.7 billion in 2023, followed by Canada and Mexico with expected values of USD 26.4 and USD 24.6 billion, respectively.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA pharmaceuticals market

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA pharmaceuticals market

- Leading company profiles reveal details of key pharmaceuticals market players' NAFTA operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA pharmaceuticals market with five year forecasts

- Compares data from the US, Canada and Mexico, alongside individual chapters on each country

Reasons to buy

- What was the size of the NAFTA pharmaceuticals market by value in 2018?

- What will be the size of the NAFTA pharmaceuticals market in 2023?

- What factors are affecting the strength of competition in the NAFTA pharmaceuticals market?

- How has the market performed over the last five years?

- Who are the top competitors in the NAFTA pharmaceuticals market?

READ MORE

Table Of Content

Scope

Table of Contents

Introduction

What is this report about?

Who is the target reader?

How to use this report

Definitions

NAFTA Pharmaceuticals

Industry Outlook

Pharmaceuticals in Canada

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Pharmaceuticals in Mexico

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Pharmaceuticals in The United States

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Company Profiles

Leading Companies

Appendix

Methodology

About MarketLine


List Of Figure

List of Figures

Figure 1: NAFTA countries pharmaceuticals industry, revenue (USD bn), 2014-23

Figure 2: NAFTA countries pharmaceuticals industry, revenue (USD bn), 2014-18

Figure 3: NAFTA countries pharmaceuticals industry forecast, revenue (USD bn), 2018-23

Figure 4: Canada pharmaceuticals market value: USD billion, 2014-18

Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2018

Figure 6: Canada pharmaceuticals market share: % share, by value, 2018

Figure 7: Canada pharmaceuticals market value forecast: USD billion, 2018-23

Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2018

Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2018

Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2018

Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2018

Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2018

Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2018

Figure 14: Mexico pharmaceuticals market value: USD billion, 2014-18

Figure 15: Mexico pharmaceuticals market geography segmentation: % share, by value, 2018

Figure 16: Mexico pharmaceuticals market share: % share, by value, 2018

Figure 17: Mexico pharmaceuticals market value forecast: USD billion, 2018-23

Figure 18: Forces driving competition in the pharmaceuticals market in Mexico, 2018

Figure 19: Drivers of buyer power in the pharmaceuticals market in Mexico, 2018

Figure 20: Drivers of supplier power in the pharmaceuticals market in Mexico, 2018

Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2018

Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2018

Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2018

Figure 24: United States pharmaceuticals market value: USD billion, 2014-18

Figure 25: United States pharmaceuticals market geography segmentation: % share, by value, 2018

Figure 26: United States pharmaceuticals market share: % share, by value, 2018

Figure 27: United States pharmaceuticals market value forecast: USD billion, 2018-23

Figure 28: Forces driving competition in the pharmaceuticals market in the United States, 2018

Figure 29: Drivers of buyer power in the pharmaceuticals market in the United States, 2018

Figure 30: Drivers of supplier power in the pharmaceuticals market in the United States, 2018

Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2018

Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2018

Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2018

Figure 34: Johnson & Johnson: revenues & profitability

Figure 35: Johnson & Johnson: assets & liabilities

Figure 36: Bayer AG: revenues & profitability

Figure 37: Bayer AG: assets & liabilities

Figure 38: Novartis AG: revenues & profitability

Figure 39: Novartis AG: assets & liabilities

Figure 40: AstraZeneca PLC: revenues & profitability

Figure 41: AstraZeneca PLC: assets & liabilities

Figure 42: Merck & Co., Inc.: revenues & profitability

Figure 43: Merck & Co., Inc.: assets & liabilities

Figure 44: Pfizer Inc: revenues & profitability

Figure 45: Pfizer Inc: assets & liabilities


List Of Table

List of Tables

Table 1: NAFTA countries pharmaceuticals industry, revenue (USD bn), 2014-23

Table 2: NAFTA countries pharmaceuticals industry, revenue (USD bn), 2014-18

Table 3: NAFTA countries pharmaceuticals industry forecast, revenue (USD bn), 2018-23

Table 4: Canada pharmaceuticals market value: USD billion, 2014-18

Table 5: Canada pharmaceuticals market geography segmentation: USD billion, 2018

Table 6: Canada pharmaceuticals market share: % share, by value, 2018

Table 7: Canada pharmaceuticals market value forecast: USD billion, 2018-23

Table 8: Canada size of population (million), 2014-18

Table 9: Canada gdp (constant 2005 prices, USD billion), 2014-18

Table 10: Canada gdp (current prices, USD billion), 2014-18

Table 11: Canada inflation, 2014-18

Table 12: Canada consumer price index (absolute), 2014-18

Table 13: Canada exchange rate, 2014-18

Table 14: Mexico pharmaceuticals market value: USD billion, 2014-18

Table 15: Mexico pharmaceuticals market geography segmentation: USD billion, 2018

Table 16: Mexico pharmaceuticals market share: % share, by value, 2018

Table 17: Mexico pharmaceuticals market value forecast: USD billion, 2018-23

Table 18: Mexico size of population (million), 2014-18

Table 19: Mexico gdp (constant 2005 prices, USD billion), 2014-18

Table 20: Mexico gdp (current prices, USD billion), 2014-18

Table 21: Mexico inflation, 2014-18

Table 22: Mexico consumer price index (absolute), 2014-18

Table 23: Mexico exchange rate, 2014-18

Table 24: United States pharmaceuticals market value: USD billion, 2014-18

Table 25: United States pharmaceuticals market geography segmentation: USD billion, 2018

Table 26: United States pharmaceuticals market share: % share, by value, 2018

Table 27: United States pharmaceuticals market value forecast: USD billion, 2018-23

Table 28: United States size of population (million), 2014-18

Table 29: United States gdp (constant 2005 prices, USD billion), 2014-18

Table 30: United States gdp (current prices, USD billion), 2014-18

Table 31: United States inflation, 2014-18

Table 32: United States consumer price index (absolute), 2014-18

Table 33: United States exchange rate, 2014-18

Table 34: Apotex, Inc.: key facts

Table 35: Johnson & Johnson: key facts

Table 36: Johnson & Johnson: key financials (USD )

Table 37: Johnson & Johnson: key financial ratios

Table 38: Bayer AG: key facts

Table 39: Bayer AG: key financials (USD )

Table 40: Bayer AG: key financials (EUR)

Table 41: Bayer AG: key financial ratios

Table 42: Novartis AG: key facts

Table 43: Novartis AG: key financials (USD )

Table 44: Novartis AG: key financial ratios

Table 45: AstraZeneca PLC: key facts

Table 46: AstraZeneca PLC: key financials (USD )

Table 47: AstraZeneca PLC: key financial ratios

Table 48: Merck & Co., Inc.: key facts

Table 49: Merck & Co., Inc.: key financials (USD )

Table 50: Merck & Co., Inc.: key financial ratios

Table 51: Pfizer Inc: key facts

Table 52: Pfizer Inc: key financials (USD )

Table 53: Pfizer Inc: key financial ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Pharmaceuticals North America (NAFTA) Industry Guide 2014-2023

Summary

The NAFTA Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the NAFTA pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

Key Highlights

- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The pharmaceuticals industry within the NAFTA countries had a total market value of USD 437.0 billion in 2018.The Mexico was the fastest growing country, with a CAGR of 4.6% over the 2014-18 period.

- Within the pharmaceuticals industry, the US is the leading country among the NAFTA bloc, with market revenues of USD 392.8 billion in 2018. This was followed by Canada and Mexico, with a value of USD 23.5 and USD 20.7 billion, respectively.

- The US is expected to lead the pharmaceuticals industry in the NAFTA bloc, with a value of USD 484.7 billion in 2023, followed by Canada and Mexico with expected values of USD 26.4 and USD 24.6 billion, respectively.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA pharmaceuticals market

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA pharmaceuticals market

- Leading company profiles reveal details of key pharmaceuticals market players' NAFTA operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA pharmaceuticals market with five year forecasts

- Compares data from the US, Canada and Mexico, alongside individual chapters on each country

Reasons to buy

- What was the size of the NAFTA pharmaceuticals market by value in 2018?

- What will be the size of the NAFTA pharmaceuticals market in 2023?

- What factors are affecting the strength of competition in the NAFTA pharmaceuticals market?

- How has the market performed over the last five years?

- Who are the top competitors in the NAFTA pharmaceuticals market?

READ MORE

Scope

Table of Contents

Introduction

What is this report about?

Who is the target reader?

How to use this report

Definitions

NAFTA Pharmaceuticals

Industry Outlook

Pharmaceuticals in Canada

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Pharmaceuticals in Mexico

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Pharmaceuticals in The United States

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Company Profiles

Leading Companies

Appendix

Methodology

About MarketLine


List Of Figure

List of Figures

Figure 1: NAFTA countries pharmaceuticals industry, revenue (USD bn), 2014-23

Figure 2: NAFTA countries pharmaceuticals industry, revenue (USD bn), 2014-18

Figure 3: NAFTA countries pharmaceuticals industry forecast, revenue (USD bn), 2018-23

Figure 4: Canada pharmaceuticals market value: USD billion, 2014-18

Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2018

Figure 6: Canada pharmaceuticals market share: % share, by value, 2018

Figure 7: Canada pharmaceuticals market value forecast: USD billion, 2018-23

Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2018

Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2018

Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2018

Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2018

Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2018

Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2018

Figure 14: Mexico pharmaceuticals market value: USD billion, 2014-18

Figure 15: Mexico pharmaceuticals market geography segmentation: % share, by value, 2018

Figure 16: Mexico pharmaceuticals market share: % share, by value, 2018

Figure 17: Mexico pharmaceuticals market value forecast: USD billion, 2018-23

Figure 18: Forces driving competition in the pharmaceuticals market in Mexico, 2018

Figure 19: Drivers of buyer power in the pharmaceuticals market in Mexico, 2018

Figure 20: Drivers of supplier power in the pharmaceuticals market in Mexico, 2018

Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2018

Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2018

Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2018

Figure 24: United States pharmaceuticals market value: USD billion, 2014-18

Figure 25: United States pharmaceuticals market geography segmentation: % share, by value, 2018

Figure 26: United States pharmaceuticals market share: % share, by value, 2018

Figure 27: United States pharmaceuticals market value forecast: USD billion, 2018-23

Figure 28: Forces driving competition in the pharmaceuticals market in the United States, 2018

Figure 29: Drivers of buyer power in the pharmaceuticals market in the United States, 2018

Figure 30: Drivers of supplier power in the pharmaceuticals market in the United States, 2018

Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2018

Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2018

Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2018

Figure 34: Johnson & Johnson: revenues & profitability

Figure 35: Johnson & Johnson: assets & liabilities

Figure 36: Bayer AG: revenues & profitability

Figure 37: Bayer AG: assets & liabilities

Figure 38: Novartis AG: revenues & profitability

Figure 39: Novartis AG: assets & liabilities

Figure 40: AstraZeneca PLC: revenues & profitability

Figure 41: AstraZeneca PLC: assets & liabilities

Figure 42: Merck & Co., Inc.: revenues & profitability

Figure 43: Merck & Co., Inc.: assets & liabilities

Figure 44: Pfizer Inc: revenues & profitability

Figure 45: Pfizer Inc: assets & liabilities


List Of Table

List of Tables

Table 1: NAFTA countries pharmaceuticals industry, revenue (USD bn), 2014-23

Table 2: NAFTA countries pharmaceuticals industry, revenue (USD bn), 2014-18

Table 3: NAFTA countries pharmaceuticals industry forecast, revenue (USD bn), 2018-23

Table 4: Canada pharmaceuticals market value: USD billion, 2014-18

Table 5: Canada pharmaceuticals market geography segmentation: USD billion, 2018

Table 6: Canada pharmaceuticals market share: % share, by value, 2018

Table 7: Canada pharmaceuticals market value forecast: USD billion, 2018-23

Table 8: Canada size of population (million), 2014-18

Table 9: Canada gdp (constant 2005 prices, USD billion), 2014-18

Table 10: Canada gdp (current prices, USD billion), 2014-18

Table 11: Canada inflation, 2014-18

Table 12: Canada consumer price index (absolute), 2014-18

Table 13: Canada exchange rate, 2014-18

Table 14: Mexico pharmaceuticals market value: USD billion, 2014-18

Table 15: Mexico pharmaceuticals market geography segmentation: USD billion, 2018

Table 16: Mexico pharmaceuticals market share: % share, by value, 2018

Table 17: Mexico pharmaceuticals market value forecast: USD billion, 2018-23

Table 18: Mexico size of population (million), 2014-18

Table 19: Mexico gdp (constant 2005 prices, USD billion), 2014-18

Table 20: Mexico gdp (current prices, USD billion), 2014-18

Table 21: Mexico inflation, 2014-18

Table 22: Mexico consumer price index (absolute), 2014-18

Table 23: Mexico exchange rate, 2014-18

Table 24: United States pharmaceuticals market value: USD billion, 2014-18

Table 25: United States pharmaceuticals market geography segmentation: USD billion, 2018

Table 26: United States pharmaceuticals market share: % share, by value, 2018

Table 27: United States pharmaceuticals market value forecast: USD billion, 2018-23

Table 28: United States size of population (million), 2014-18

Table 29: United States gdp (constant 2005 prices, USD billion), 2014-18

Table 30: United States gdp (current prices, USD billion), 2014-18

Table 31: United States inflation, 2014-18

Table 32: United States consumer price index (absolute), 2014-18

Table 33: United States exchange rate, 2014-18

Table 34: Apotex, Inc.: key facts

Table 35: Johnson & Johnson: key facts

Table 36: Johnson & Johnson: key financials (USD )

Table 37: Johnson & Johnson: key financial ratios

Table 38: Bayer AG: key facts

Table 39: Bayer AG: key financials (USD )

Table 40: Bayer AG: key financials (EUR)

Table 41: Bayer AG: key financial ratios

Table 42: Novartis AG: key facts

Table 43: Novartis AG: key financials (USD )

Table 44: Novartis AG: key financial ratios

Table 45: AstraZeneca PLC: key facts

Table 46: AstraZeneca PLC: key financials (USD )

Table 47: AstraZeneca PLC: key financial ratios

Table 48: Merck & Co., Inc.: key facts

Table 49: Merck & Co., Inc.: key financials (USD )

Table 50: Merck & Co., Inc.: key financial ratios

Table 51: Pfizer Inc: key facts

Table 52: Pfizer Inc: key financials (USD )

Table 53: Pfizer Inc: key financial ratios

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS